AA
HRMY icon

AlphaCentric Advisors’s Harmony Biosciences HRMY Stock Holding History

AlphaCentric Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-97,000
Closed -$3.88M – 247
2024
Q3 		$3.88M Sell
97,000
-25,000
-20% -$878K 2.88% 2
2024
Q2 		$3.68M Hold
122,000
– – 2.71% 5
2024
Q1 		$4.1M Hold
122,000
– – 2.47% 3
2023
Q4 		$3.94M Hold
122,000
– – 2.65% 5
2023
Q3 		$4M Buy
122,000
+4,000
+3% +$139K 2.27% 4
2023
Q2 		$4.15M Buy
118,000
+50,500
+75% +$1.74M 2.3% 3
2023
Q1 		$2.2M Buy
+67,500
New +$3.07M 1.52% 14

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

AlphaCentric Advisors's HRMY Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Harmony Biosciences (HRMY) in Q4 2024, closing a stake of 97,000 shares — an estimated $3.88M sold.

AlphaCentric Advisors first reported a position in HRMY in Q1 2023 and held it in 7 quarters. The position peaked at $4.15M in Q2 2023. 247 funds tracked by Wall St. Rank hold HRMY as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Harmony Biosciences position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 97,000 Harmony Biosciences shares in Q4 2024, an estimated $3.88M.
  • AlphaCentric Advisors first reported a position in Harmony Biosciences in Q1 2023 and held it in 7 quarters.
  • AlphaCentric Advisors's Harmony Biosciences position peaked at $4.15M in Q2 2023.
  • 247 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.